All News
Filter News
Found 139 articles
-
Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting
10/28/2019
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the results of a Phase 2 study of NYX-2925 in patients with fibromyalgia have been selected for a late-breaking poster presentation at the American College of Rheumatology Annual Meeting
-
Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th Annual Meeting of the Society for Neuroscience
10/15/2019
The poster presentations will highlight preclinical data from three of Aptinyx’s clinical-stage product candidates that are in development for chronic pain, PTSD, and cognitive impairment.
-
Osage University Partners Closes Oversubscribed $273 Million Third Venture Fund for University Startups
3/12/2019
Osage University Partners, a Philadelphia area-based venture capital firm, announced the closing of Osage University Partners III, L.P. at $273 million, exceeding its target of $250 million.
-
ViaCyte Announces New Board Members
1/29/2019
ViaCyte, Inc., a privately-held regenerative medicine company, today announced that following the recent $80 million Series D financing, the Company's Board of Directors has been restructured.
-
Shares of Illinois-based Aptinyx Inc. have plunged more than 67 percent in premarket trading after the company announced its mid-stage treatment for painful diabetic peripheral neuropathy failed to show statistical significance.
-
AstraZeneca has indicated it plans to lay off 210 people in Boulder and Longmont. The reason is the company is consolidating “the biologics manufacturing network in one large-scale drug substance facility” in Frederick, Maryland.
-
With the J.P. Morgan Healthcare Conference winding down, companies remain busy striking deals and informing investors about pipeline advances. BioSpace snagged some of the interesting news bits to come out of the conference from Wednesday.
-
Cerevel Therapeutics Expands Its Board of Directors
12/20/2018
New Members Include Experienced Company Builders and Life Science Leaders
-
Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy
11/1/2018
Top-line Data Expected Early in the First Quarter of 2019
-
Bain Capital and Pfizer Create Cerevel Therapeutics, New CNS Company
10/23/2018
Continues Development of Neuroscience Portfolio, Aiming to Bring New Therapies to Patients
-
Depression Awareness Month: Ketamine Clinics Put Not-Always Flattering Spotlight on Treatment
10/15/2018
Depression affects almost 20 million Americans yearly and major depressive disorders affect nearly 300 million people worldwide. The annual market for these disorders is approximately $83 billion. -
Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD)
7/23/2018
New Molecule Recognized as a Potentially Innovative Treatment for MDD, a Serious Condition with Persistent Unmet Need
-
Aptinyx Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
6/25/2018
Aptinyx Inc. announced the closing of its initial public offering of 7,359,998 shares of common stock at a public offering price of $16.00 per share
-
Autolus Brings in $150 Million in IPO, Continues Strong Investment Trend for Biotechs This Week
6/22/2018
Autolus Therapeutics snagged $150 million from its initial public offering, about $25 million more than the company initially expected when it began its roadshow effort earlier this month. -
It’s a super-busy week for biotech initial public offerings (IPOs) with six companies raking in a total of around $568 million.
-
Aptinyx Announces Pricing of Initial Public Offering
6/21/2018
Pricing of its initial public offering of 6,399,999 shares of its common stock at a public offering price of $16.00 per share.
-
Axial Biotherapeutics Announces Neurology Scientific and Clinical Advisory Board
6/12/2018
Axial Biotherapeutics today announced the appointment of renowned researchers and thought leaders with expertise in neurology, Parkinson’s disease and regulatory strategy to its scientific and clinical advisory board.
-
Six Biotechs Launch IPO Plans in Last Days of May, While Iterum Therapeutics Adjusts IPO Goals
5/29/2018
It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs. -
A day after Illinois-based Aptinyx strengthened its relationship with pharma giant Allergan, the company is now eying an $80 million initial public offering of stock on the Nasdaq Exchange.
-
Allergan has exercised an option to acquire an oral small molecule compound from Illinois-based Aptinyx, a spinout of Naurex, Inc., which the Irish company acquired in 2015. The company will use it as a complement to a Phase III depression treatment.